Colgate-Palmolive (CL) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Colgate-Palmolive published the results on October 30, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Colgate-Palmolive reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Base Business EPS (non-GAAP), which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Colgate-Palmolive recast its geographic segments to the reporting structure effective for the quarter ended March 31, 2026; year-ago regional figures are the recast ones.
• Base Business EPS excludes charges from the Strategic Growth and Productivity Program, $0.03 a share in Q3 2026.

Source: Colgate-Palmolive Q3 2026 results, October 30, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Colgate-Palmolive splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Colgate-Palmolive's Oral, Personal and Home Care revenue was $4.2 billion in Q3 2026, up 4% from $4.0 billion in Q3 2025, 78% of total revenue.
• Colgate-Palmolive's Hill's Pet Nutrition revenue was $1.2 billion in Q3 2026, up 6% from $1.1 billion in Q3 2025, 22% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Colgate-Palmolive narrowed its net sales guidance and raised its gross profit margin and Base Business EPS guidance with these results.

In its Q3 2026 release, Colgate-Palmolive said:

“The Company now expects net sales to be up 4% to 5% (versus 2% to 6% previously), including a low-single-digit positive impact from foreign exchange.”

“The Company now expects organic sales growth to be broadly in line with its nine-month performance (versus 1% to 4% previously). This includes the impact from our exit from the private label pet food business.”

“On a GAAP basis, the Company now expects gross profit margin to be up (versus roughly flat previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales and double-digit earnings per share growth.”

“On a non-GAAP (Base Business) basis, the Company now expects gross profit margin to be up (versus roughly flat previously) and still expects advertising to be up on both a dollar basis and as a percentage of net sales; it also now expects 5% to 7% earnings per share growth (versus mid-single-digit growth previously).”

Source: Colgate-Palmolive Q3 2026 release, Oct 30, 2026.

This is the company's own guidance as of Oct 30, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CL forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release. The Q4 2025 loss per share reflects goodwill and intangible assets impairment charges related to the skin health business.

Colgate-Palmolive's next report is expected around January 29, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 30, 2026

Colgate-Palmolive reports two product segments. Oral, Personal and Home Care, split into four regions, had net sales of $4,164 million in Q3 2026, and Hill's Pet Nutrition had $1,205 million, for a total of $5,369 million. By category, Oral Care was 44% of net sales, Pet Nutrition 23%, Personal Care 17% and Home Care 16%. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026; Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

Net sales rose 4.6%, made up of volume growth of 1.7%, pricing of 2.0% and foreign exchange of 1.0%. Organic sales, which exclude currency, acquisitions and divestments, rose 3.6%, including a 0.2% negative impact from lower private label pet food sales. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026; Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

Latin America grew fastest: net sales rose 12.5% to $1,326 million, with organic growth of 6.0% led by Brazil, Argentina and Colombia, and foreign exchange added 6.5%. North America was the one region down, with net sales off 1.7% and volume down 3.7%, which Colgate-Palmolive attributes to declines in Personal Care and Oral Care organic sales in the United States. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026; Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

Hill's Pet Nutrition net sales rose 5.6%, mostly on pricing of 3.9%, with organic growth of 5.7% led by the United States and Europe in the therapeutic and wellness categories. Lower private label pet food sales took 70 bps off Hill's organic growth. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026; Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

About two-thirds of Colgate-Palmolive's net sales come from outside the United States, and about 45% from emerging markets. Walmart, Inc. and its affiliates accounted for approximately 11% of net sales in 2025, and no other customer for more than 10%. (Colgate-Palmolive Form 10-K, 2025, Feb 23, 2026)

Colgate-Palmolive's GAAP diluted EPS was $0.94 in Q3 2026, up 3%, and Base Business EPS was $0.97, up 7%. The gap is the Strategic Growth and Productivity Program: $30 million of pre-tax charges ($26 million after tax), or $0.03 a share. Base Business results exclude that program, the ERISA litigation matter and acquisition-related costs. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026; Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

Over the first nine months the program cost $333 million pre-tax ($268 million after tax). Colgate-Palmolive expanded it on April 30, 2026 and estimates its cumulative pre-tax charges at between $350 and $550 million, with substantially all incurred by December 31, 2028. (Colgate-Palmolive Form 10-Q, Q3 2026, Oct 30, 2026)

Diluted shares averaged 799.7 million, against 810.2 million a year earlier, and the company spent $927 million buying back shares in the first nine months. The effective tax rate rose to 23.6% from 22.8%, and advertising spending rose to $775 million from $674 million. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Colgate-Palmolive gives qualitative full-year guidance in its release, based on current spot rates. With Q3 2026 it now expects 2026 net sales up 4% to 5% (versus 2% to 6% previously), organic sales growth broadly in line with its nine-month performance (versus 1% to 4% previously), and Base Business EPS growth of 5% to 7% (versus mid-single-digit growth previously). (Colgate-Palmolive Q3 2026 release, Oct 30, 2026)

On a GAAP basis it now expects gross profit margin to be up and still expects double-digit EPS growth, with advertising up in dollars and as a percentage of net sales. Nine-month organic sales growth, the yardstick for its organic guidance, was 3.0%. (Colgate-Palmolive Q3 2026 release, Oct 30, 2026)

A consensus figure is the average of the models published by the analysts who cover Colgate-Palmolive, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Colgate-Palmolive's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CL is on is CL a buy or a sell?, what analysts expect next is on the CL forecast, and what the company does is on the Colgate-Palmolive (CL) stock page.

Every number on this page can be traced to a document Colgate-Palmolive published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.